Developing a new HIV vaccine using RNA technology
Official title: RNA-based HIV-1 chimera vaccines encoding a trimerizing host self-protein protomer linked to a viral MPER-TM segment
Funded at Dana-Farber Cancer Inst · NIH-11062370 · Data updated 2026-11-12
This study is testing a new type of HIV vaccine that uses special technology to help your immune system recognize and fight the virus, aiming to provide better protection for people living with HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $2,256,224 |
| NIH project number | 5P01AI181597-02 |
| Project ID | NIH-11062370 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who are already effectively managing their HIV with existing treatments may not benefit from this research.
What this research studies
This research focuses on creating a novel vaccine for HIV-1 that aims to generate broadly neutralizing antibodies (bnAbs) to combat the virus's rapid mutation. The approach involves using RNA-based technology to encapsulate specific viral protein segments, which are designed to stimulate the immune system effectively. By targeting a conserved region of the virus that is critical for its ability to infect cells, the researchers hope to enhance the immune response and provide better protection against HIV. The study will involve advanced techniques such as lipid nanoparticles to deliver the vaccine components safely and effectively.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking vaccine that provides long-lasting immunity against HIV-1.
How similar studies have gone: While the approach is innovative, previous research has shown promise in developing vaccines targeting similar viral components, indicating potential for success.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Reinherz, Ellis L — Dana-Farber Cancer Inst
- Study coordinator: Reinherz, Ellis L
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.